Metformin (Longevity).

Metformin interferes with the calcium-dependent step that lets the intrinsic factor and B12 complex attach to its receptor in the lower small intestine, so long-run users drift down in B12 status. Supplemental B12 keeps the vitamin in normal range.

The same ileal uptake block applies whichever cobalamin form is eaten, and methylcobalamin is the form methionine synthase uses directly. Co-supplying it maintains one-carbon methyl transfer while metformin is in use.

The intrinsic factor and B12 complex needs free calcium to bind its ileal receptor, and metformin disturbs that calcium-dependent step. Adding calcium has been reported to restore the binding step, on a small evidence base.

Both metformin and thiamine are organic cations carried into liver cells by OCT1, so they use the same doorway. The transporter sharing is established pharmacology; how much it moves thiamine status in practice is less settled.

Folate and B12 work as a pair in methyl transfer, and folate status is reported to trend down alongside B12 in long-run metformin users. Supplying folate keeps the methylation cycle turning while B12 is being replaced.

Berberine and metformin both damp mitochondrial complex I and switch on AMPK, the cell's low-energy sensor, so their effects on glucose handling run along one axis. Because the axis is shared, the pairing is additive rather than complementary.

Inositol phosphoglycans act as second messengers downstream of the insulin receptor, a different entry point from metformin's AMPK route into the same glucose-handling pathway. The two enter one pathway at separate points.

Metformin inhibits mitochondrial complex I, the entry point of the electron transport chain that coenzyme Q10 shuttles electrons out of. That places the two on the same chain from opposite directions. No trial of the pair was retrieved and any use alongside a prescription medicine belongs with the prescriber.

Alpha-lipoic acid is studied for insulin sensitivity markers in adults with high blood sugar, the same direction metformin moves. Added together the glucose-lowering effects can stack, which is a monitoring point rather than a benefit to assume. Dose decisions here are the prescriber's.

Chromium is involved in normal macronutrient metabolism and is studied for fasting glucose markers. Layered onto metformin the effects on blood sugar point the same way. Anyone combining them needs glucose monitoring rather than a fixed rule.

Gymnema is traditionally used for blood sugar support and appears in formulas aimed at the same audience metformin is prescribed to. The evidence base is thin and the direction of effect overlaps. Additive glucose lowering is the thing to flag.

Bitter melon contains compounds studied for glucose uptake in cell and animal models and is used traditionally for blood sugar support. Its effect direction matches metformin's. Combining them without monitoring risks pushing glucose lower than intended.

Cinnamon extracts have been studied for fasting glucose and insulin markers with inconsistent results. Where an effect appears it moves in the same direction as metformin. The additive possibility is worth stating even though the evidence is uneven.

Mulberry leaf supplies 1-deoxynojirimycin, an alpha-glucosidase inhibitor that slows carbohydrate breakdown in the gut lumen. Metformin works after absorption, on hepatic glucose output and insulin sensitivity. Different mechanisms, same direction on post-meal glucose, so the effect is additive.

Part of metformin's action is exerted in the gut, and it shifts microbial composition. Adding a fermentable fibre like inulin loads the same compartment with substrate. The practical consequence is gas and bloating on top of metformin's own gastrointestinal profile.

Psyllium forms a gel that slows gastric emptying and can slow the absorption of anything taken in the same dose, including an oral medicine. Separating a viscous fibre from a prescription dose by a couple of hours is the standard handling. This is a timing interaction, not a reason either cannot be used.

Metformin changes gut microbial composition, and live cultures are added to the same compartment. Whether one modifies the other's effect has not been established in the retrieved literature. It is a plausible interaction site, nothing more.

Betaine donates a methyl group to convert homocysteine back to methionine through betaine-homocysteine methyltransferase, a route independent of B12 and folate. Because long-term metformin use is associated with lower B12 status, the alternate methylation route is mechanistically relevant. Homocysteine is a marker, and this row is about the pathway rather than a measured outcome.

NR raises NAD+ availability, and metformin's complex I inhibition shifts the cellular NAD+ to NADH ratio and activates AMPK. Both are discussed inside the same energy-sensing story in geroscience reviews. No human study of the pair was retrieved.

NMN is another NAD+ precursor discussed alongside metformin in longevity-focused reviews. The overlap is at the level of AMPK and sirtuin signalling described in cell and animal work. Nothing retrieved tested the combination in people.

Resveratrol activates AMPK and sirtuin signalling in cell and animal models, the same node metformin reaches through the AMP to ATP ratio. Both are named in the geroscience literature as candidate interventions. Human combination data was not retrieved.

Carnitine carries long-chain fatty acids into the mitochondrion for beta-oxidation, a process constrained when complex I activity is reduced. That places carnitine and metformin on the same mitochondrial substrate handling. The interaction is mechanistic and has not been quantified in the retrieved record.

Taurine is studied for glucose and lipid markers and is named among candidate geroprotective molecules. Its mechanisms do not converge with metformin's in any documented way. The row records the shared context, not a demonstrated interaction.

Magnesium is a cofactor for the kinases of insulin signalling and for hundreds of ATP-dependent reactions, and urinary magnesium loss rises when glucose spills into urine. It sits alongside metformin in the same metabolic picture without acting on the same target. Status matters more here than a stacking effect.

Lower vitamin D status is associated with poorer glucose-handling markers in observational data, and association is not cause. Metformin does not act on vitamin D metabolism in any established way. The pairing is a status question, not an interaction.

The retrieved mechanistic work identifies amino acid homeostasis as a target of metformin, which puts branched-chain amino acid handling inside its effect radius. Leucine is the branched-chain amino acid most often supplemented on its own. The finding is mechanistic and does not establish an effect of the combination in people.